# Hydroxyurea in the Treatment of Sickle Cell Disease

> **NCT02709681** · — · COMPLETED · sponsor: **Società Italiana Talassemie ed Emoglobinopatie** · enrollment: 628 (actual)

## Conditions studied

- Sickle Cell Disease

## Interventions

- **OTHER:** Physician standard-of-care in SCD patients

## Key facts

- **NCT ID:** NCT02709681
- **Lead sponsor:** Società Italiana Talassemie ed Emoglobinopatie
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11
- **Primary completion:** 2016-11
- **Final completion:** 2017-07
- **Target enrollment:** 628 (ACTUAL)
- **Last updated:** 2017-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02709681

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02709681, "Hydroxyurea in the Treatment of Sickle Cell Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02709681. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*